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Abstract
Background: Toxoplasma gondii, an obligate intracellular apicomplexan parasite, infects a wide range of warm-
blooded animals including humans. T. gondii expresses five members of the C1 family of cysteine proteases,
including cathepsin B-like (TgCPB) and cathepsin L-like (TgCPL) proteins. TgCPB is involved in ROP protein
maturation and parasite invasion, whereas TgCPL contributes to proteolytic maturation of proTgM2AP and
proTgMIC3. TgCPL is also associated with the residual body in the parasitophorous vacuole after cell division has
occurred. Both of these proteases are potential therapeutic targets in T. gondii. The aim of this study was to
investigate TgCPB and TgCPL for their potential as DNA vaccines against T. gondii.
Methods: Using bioinformatics approaches, we analyzed TgCPB and TgCPL proteins and identified several linear-B
cell epitopes and potential Th-cell epitopes in them. Based on these results, we assembled two single-gene
constructs (TgCPB and TgCPL) and a multi-gene construct (pTgCPB/TgCPL) with which to immunize BALB/c mice
and test their effectiveness as DNA vaccines.
Results: TgCPB and TgCPL vaccines elicited strong humoral and cellular immune responses in mice, both of which
were Th-1 cell mediated. In addition, all of the vaccines protected the mice against infection with virulent T. gondii
RH tachyzoites, with the multi-gene vaccine (pTgCPB/TgCPL) providing the highest level of protection.
Conclusions: T. gondii CPB and CPL proteases are strong candidates for development as novel DNA vaccines.
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Background
The obligate intracellular apicomplexan parasite Toxo-
plasma gondii infects a wide range of warm-blooded ani-
mals and causes the anthropozoonotic disease known as
toxoplasmosis on a worldwide scale [1,2]. T. gondii infec-
tion is usually invisible to the host, causing no symptoms
or mild ones; however, severe disease complications can
occur in immunocompromised individuals and newborns
[3,4]. Toxoplasmic encephalitis can emerge as a life-
threatening condition in patients infected with the human
immunodeficiency virus when reactivation of the cyst
stage of T. gondii occurs in the brain [5]. In addition, ani-
mal studies show that T. gondii infection can have a far-
reaching influence on host behavior, neuronal function
and mate choice. Brain cysts in rats that are chronically
infected with T. gondii alter the rats’ exploratory and risk
taking behavior and unconditioned fear responses, which
can lead to greater opportunities for transmission of the
parasite from the intermediate rodent host to the defini-
tive host, the cat [6]. T. gondii can also enhance the sexual
attractiveness of infected male rats [7]. T. gondii
tachyzoites actively manipulate Ca2+ signaling upon glu-
tamate stimulation, leading to neuronal hypo- or hyper-
responsivity in the host [8]. Unfortunately, there are no
drug treatments available to cure toxoplasmosis. In recent
years, the possibility that DNA vaccines, which have the
capacity to induce continuous and strong protective
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immune responses, could be an option for eliminating this
ubiquitous parasite has been raised [9,10].
An important design principle for DNA vaccines is
the selection of parasite proteins involved in the host
cell invasion process by T. gondii; therefore, many
researchers are working to identify the relevant
proteins that may be developed as vaccines against
toxoplasmosis [11].
Cysteine proteases play many specialized roles in the
body, including endocytosis-related polypeptide degrad-
ation [12], tumor invasion [13] and TNF α-induced
apoptosis [14]. More importantly, cysteine proteases are
important for the growth and survival of apicomplexan
parasites that infect humans. T. gondii expresses five
members of the C1 family of cysteine proteases, includ-
ing one cathepsin B-like (TgCPB), one cathepsin L-like
(TgCPL), and three cathepsin C-like (TgCPC1, 2 and 3)
proteases [15]. Among these, TgCPB and TgCPL are
mainly expressed in the vacuolar compartment, but a
tiny amount of TgCPL has been identified in the late en-
dosome [16-19]. These proteases are thought to function
in protein degradation and play specialized roles in the
maturation of invasion-related proteins. TgCPB is in-
volved in ROP protein maturation and parasite invasion
[16]. In contrast, TgCPL contributes to proteolytic mat-
uration of proTgM2AP and proTgMIC3, and is also as-
sociated with the residual body in the parasitophorous
vacuole after cell division [20-23].
T. gondii cathepsins are considered potential thera-
peutic targets based on the results of the following gen-
etic and inhibitor studies: antisense inhibition of TgCPB
expression or treatment with cathepsin inhibitors dimin-
ished parasite replication, cell invasion and infection
in vivo [16,24]; genetic disruption of TgCPL diminished
parasite cell invasion and growth [17]; and, the cathepsin
inhibitor morpholinurea-leucyl-homophenyl-vinyl sul-
fone phenyl inhibited parasite invasion by blocking the
release of invasion proteins from microneme secretory
organelles [25,26]. To our knowledge, no studies have
described the induction of protective immune responses
against T. gondii CPB and CPL in the host. We propose
that a DNA vaccine construct based on TgCPB and TgCPL
could be a useful tool against disease caused by T. gondii.
Hence, in this study, we used bioinformatics ap-
proaches to analyze TgCPB and TgCPL, the results of
which identified a large number of linear-B cell epitopes
and potential Th-cell epitopes on these proteases. This
suggested the possibility that TgCPB and TgCPL could
be used as vaccines. Based on the results of the epitope
analyses, pTgCPB and pTgCPL were constructed as
single-gene vaccines and pTgCPB/TgCPL as a multi-
gene vaccine, and their immunogenicity, protective ef-
ficacy, and potential as vaccine candidates against
T. gondii infection were examined in laboratory mice.
Methods
Prediction of protein secondary structure and linear-B cell
epitopes
Epitopes are the foundation of protein antigenicity that
determines antigen specificity [27,28]. There are many
types of epitope prediction methods in use, inclu-
ding hydrophilicity, accessibility, antigenicity, flexibility,
charge distribution and secondary structure [29-34].
Despite the lack of an infallible method to predict anti-
genic epitopes, several rules can be followed to deter-
mine which peptide fragments of a protein are likely to
be antigenic. Firstly, antigenic epitopes should be located
in solvent-accessible regions and contain both hydro-
phobic and hydrophilic residues. Secondly, peptides lying
in long loops connecting secondary structure motifs
should be selected preferably, while peptides located in
helical regions should be avoided. Whenever possible,
peptides that are in the N- and C-terminal regions of
the protein should be chosen because they are usually
solvent accessible and unstructured.
According to the rules outlined above, we analyzed the
linear-B cell epitopes of TgCPB and TgCPL using
DNAStar software and chose peptides that have good
hydrophilicity, high accessibility, satisfactory flexibility
and strong antigenicity. Thereafter, we used DNAMAN
software to search for linear-B cell epitopes in the
TgCPB and TgCPL amino acid sequences.
Prediction of Th-cell epitopes
T. gondii is an obligate intracellular parasite; hence, cel-
lular immunity mediated by T cells plays an important
role in T. gondii infection [35]. To develop an effective
vaccine against toxoplasmosis, it is necessary to eluci-
date which type of Th cell-mediated immune response is
necessary. Predicting Th cell epitopes is currently rather
complicated and the results are ambiguous; however,
there are some rules that can be used to predict Th cell
epitopes [36,37]. Here, we used the Immune Epitope
Database (http://tools.immuneepitope.org/analyze/html/
mhc_II_binding.html) online service to predict the half
maximal inhibitory concentration (IC50) values of pep-
tides binding to the major histocompatibility complex
(MHC) class II molecules of TgCPB and TgCPL. We
also used SYFPEITHI (http://www.syfpeithi.de/Scripts/
MHCServer.dll/EpitopePrediction.htm) to determine the
ligation strength to a defined HLA (or H2) type for
TgCPB and TgCPL. Note that such binding to MHC is
necessary but not sufficient for recognition by T cells.
Parasites and mice
Female 6-week-old BALB/c mice were purchased from
Shandong University Laboratory Animal Center. All
mice were maintained under specific pathogen-free con-
ditions. All of the animal experiments were approved by
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the Ethics Committee on Animal Experiments of the
Medical School of Shandong University.
The T. gondii RH strain was harvested from the peri-
toneal fluid of the BALB/c mice 72 h after infection, and
was washed by centrifugation and resuspended in sterile
PBS. Half of the T. gondii tachyzoite suspension was used
to extract total RNA and genomic DNA, while the other
half was used to prepare soluble tachyzoite antigens
(STAg) using an ultrasonic disintegrator. STAg prepara-
tions were aliquoted and stored at −80°C until use.
Construction of expression plasmids
The whole TgCPB gene was amplified from T. gondii total
RNA by reverse transcription polymerase chain reaction
(PCR) using the two primer pairs shown below. TgCPB for
prokaryotic expression used the following primers plasmid
construction: 5′-cgGAATTCATGGAGGGGCGAAAGTC-
3′ (forward) and 5′-ccgCTCGAGCTACATTTCTCTC
TCCTCTTCTG-3′ (reverse), both of which contain EcoRI/
XhoI restriction sites (underlined). Plasmid construction
for eukaryotic expression of TgCPB consisted of 5′-ataagaat
GCGGCCGCATGGAGGGGCGAAA-GTC-3′ (forward)
and 5′-ccgCTCGAGCTACATTTCTCTCTCCTCTTCTG-
3′ (reverse), both of which contain NotI/XhoI restriction
sites (underlined).
The whole TgCPL gene was PCR amplified from of T.
gondii genomic DNA using the two primer pairs described
below. Prokaryotic expression plasmid construction
for TgCPL used the following primers: 5′-cgGAAT
TCATGGACAGCAGCGAGACGC-A-3′ (forward) and
5′-ccgCTCGAGTCACATCACGGGGAAAGACG-3′ (re-
verse); EcoRI and XhoI restriction sites are underlined.
Eukaryotic expression plasmid construction for TgCPL
used the following primers: 5′-ccAAGCTTATGGA
CAGCA-GCGAGACGCA-3′ (forward) and 5′-gcTCTA
GATCACATCACGGGGAAAGACG-3′ (reverse); HindIII
and XbaI restriction sites are underlined.
The PCR products for both genes were cloned into a
pEASY-T1 vector (TransGen Biotech, China) to generate
a recombinant cloning plasmid. After sequencing, TgCPB
and TgCPL were subcloned into a eukaryotic expression
plasmid pET-30a(+) (Novagen, USA) and the prokaryotic
expression plasmid, pBudCE4.1 (Invitrogen, USA) to pro-
duce pET30a-TgCPB, pET30a-TgCPL, pBudCE4.1-TgCPB
and pBudCE4.1-TgCPL. Finally, TgCPB and TgCPL were
concurrently subcloned into the prokaryotic expression
plasmid pBudCE4.1 to produce pBudCE4.1-TgCPB-
TgCPL.
TgCPB and TgCPL expression in Escherichia coli and
antigen production
pET30a-TgCPB and pET30a-TgCPL constructs were
used to transform E. coli BL21(DE3) cells, which were
then grown in Luria-Bertani medium with kanamycin
(25 μg/mL). Synthesis of recombinant TgCPB and
TgCPL proteins was induced using 1mM isopropyl-β-D-
thiogalactoside for 6 or 8 h at 25°C. The cells were then
lysed and centrifuged at 4°C for 15 min at 10,000 × g.
Recombinant proteins were then purified via binding of
their carboxy terminal histidine tags to Ni-NTA resin
(Sangon Biotech, China).
Experimental mice were subcutaneously immunized
with 100 μg of purified rTgCPB or rTgCPL prepared in
equal volumes of Freund’s complete adjuvant for the first
immunization. The second and third immunizations
contained 50 μg of the purified protein in Freund’s in-
complete adjuvant. Samples of antisera were collected 2
weeks after the last immunization.
Examination of antibody specificity by western blotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blotting were used to investigate
antibody specificity, as described previously [38]. STAg
preparations were removed from the ultra-low temperature
freezer and 500 ng of each preparation was used for SDS-
PAGE. The separated protein bands were transferred onto
polyvinylidene difluoride (PVDF) membranes (Millipore,
USA), each of which was blocked with 5% w/v skimmed
milk powder diluted in PBS for 2 h at room temperature
before separate incubation with mouse anti-TgCPB or anti-
TgCPL antibodies, or pre-immune mouse sera (dilution
1:600). After a wash in PBS-Tween 20, each of the mem-
branes was incubated with diluted goat anti-mouse IgG
horseradish peroxidase (HRP)-labeled secondary antibody
(1:10,000; Sigma, USA) for 1h. Parasite proteins were visu-
alized using electrochemiluminescence reagents (Cowin
Biotech, China).
TgCPB and TgCPL expression in mammalian cells
When the cell density reached 80–90%, HEK293 cells
were transfected with pBudCE4.1-TgCPB or pBudCE4.1-
TgCPL using Lipofectamine™ 2000 reagent (Invitrogen,
USA). After 24-h incubation, the cells were fixed with
cold methanol for 20 min and protein expression was
evaluated using an indirect fluorescence antibody test as
previously described [39]. Briefly, anti-TgCPB or anti-
TgCPL antibodies were used as primary antibodies and a
FITC-labeled goat anti-mouse IgG antibody (ZSGB-Bio,
China) was used as the secondary antibody. After rinsing
three times with PBS, the coverslips were immediately
observed under a fluorescence microscope (Carl Zeiss,
Germany). The cells were then lysed with RIPA Lysis
Buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1% Triton
X-100; 1% sodium deoxycholate; 0.1% SDS) containing 1
mM of the protease inhibitor phenylmethanesulfonyl
fluoride, after which they were centrifuged at 12,000 × g
for 10 min, at either 24 h or 48 h post-transfection.
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SDS-PAGE and western blot analysis
Protein production from HEK293 cells was monitored
by SDS-PAGE and western blotting. About 500 ng of
the purified rTgCPB or rTgCPL proteins were separated
using SDS-PAGE. The separated protein bands were
transferred onto PVDF membranes. The detailed proce-
dures are the same as in the above section “Identification
of the antibody specificity by western blotting”.
Animal experiments
Five groups of BALB/c mice (n = 13 each) were individu-
ally injected 4 times at two-weekly intervals with one of
the following: PBS, pBudCE4.1, pTgCPB, pBudCE4.1-
TgCPL or pBudCE4.1-TgCPB-TgCPL. Two weeks after
the final immunization, the mice were challenged by in-
traperitoneal (i.p.) injection of 100 μL of PBS containing
1 × 104 T. gondii tachyzoites and the survival time of
each mouse was recorded.
Antibody assays
The levels of IgG antibodies against T. gondii were ana-
lyzed using an enzyme-linked immunosorbent assay
(ELISA) [40]. The microtiter plates (Costar, USA) were
coated with STAg (10 pmol/well) and incubated at 4°C
overnight. After washing three times with PBS-T, the
plates were blocked with 1% bovine serum albumin for 1
h at 37°C. The plates were washed a further three times
and incubated with the mouse sera diluted in PBS for 1
h at 37°C. After three washes, secondary goat anti-
mouse IgG, IgG1 or IgG2a conjugated with HRP (Sigma)
was added and incubated at 37°C for 1 h. Immune
complexes were revealed by incubating with ortho-
phenylenediamine (Sigma) and 0.15% H2O2 for 30 min.
Reactions were stopped by the addition of 2 M H2SO4
and read at 490 nm with an ELISA plate reader (EL800;
Bio-Tek, USA). All samples were run in triplicate.
Cytokine assays
Cytokine levels were detected according to the previously
described method [39]. Briefly, three mice per group on
week 4 after the final immunization were euthanized and
their spleens removed under sterile conditions. Viable
splenocytes were dispensed into 96-well plates at 37°C in
5% CO2 and the cell-free supernatants were harvested and
assayed for IL-4 levels at 24 h, or at 72h for IL-10, or at
96 h for IFN-γ using an ELISA kit (R&D Systems, USA).
Statistical analyses
Statistical analyses were performed using SPSS software.
Antibody production and cytokine levels among the dif-
ferent groups were determined using a one-way analysis
of variance. Survival times in the mice were compared
using the Kaplan-Meier method. Values of P < 0.05 were
considered statistically significant.
Table 1 Linear-B cell antigenic epitope prediction for TgCPB
Order Amino acid
position
Potential antigenic sequences Score
1 325–346 LMPLSAQHTTSCCNAIHCASFG 1.190
2 6–30 SFRVLGTPLPFAALAAILLLGCMYT 1.183
3 57–86 AEDVLNAFVSPESVESLFDSIVAEQVVATS 1.176
4 379–407 CWPYEVPFCAHHAKAPFPDCDATLVPRKT 1.175
5 118–127 GELLRLLLAD 1.170
6 147–160 RHIVRDSVLVSEKA 1.164
7 283–294 AFPACKDVVGHV 1.157
8 453–489 GPVSGAFMVYEDFLSYKSGVYKHVSGLPVGGHAIKII 1.153
9 196–204 SNAAVALIK 1.130
10 300–306 CGSCWAF 1.108
11 243–250 GTFLVNTK 1.103
12 225–236 EVSLRFRYLSLK 1.092
13 272–278 EPVPAHF 1.091
14 314–320 DRLCIRS 1.084
15 38–44 DSLFPLS 1.078
16 434–440 TSAYSLR 1.067
17 139–145 FRHLTHS 1.061
18 420–426 ADNVHPF 1.060
19 362–367 KGVVTG 1.055
20 260–265 MPLPAK 1.045
21 520–525 MGQCGI 1.039
Table 2 Linear-B cell antigenic epitope prediction for TgCPL
Order Amino acid position Potential antigenic sequences Score
1 60–82 RAWIALVAAAVSLLVFASFLIQW 1.205
2 364–372 DHGVLLVGY 1.168
3 142–151 KNNLVYIHTH 1.152
4 303–320 RAQSCEKVVKILGFKDVP 1.152
5 89–100 AVFPPSPVEDHQ 1.152
6 35–44 PSPPFVVTTR 1.152
7 187–209 KSHHLGVATELLNVLPSELPAGV 1.141
8 410–419 QCGLLLDASF 1.138
9 214–221 RGCVTPVK 1.136
10 6–12 THYVSFL 1.130
11 328–341 KAALAKSPVSIAIE 1.120
12 278–297 FQYVLDSGGICSEDAYPYLA 1.119
13 239–255 EGAHCAKTGKLVSLSEQ 1.110
14 226–232 CGSCWAF 1.108
15 347–362 FQFYHEGVFDASCGTD 1.100
16 113–127 FQDAFSSFQAMYAKS 1.050
17 175–180 RKYLGF 1.035
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Table 3 IC50 values for TgCPB and TgCPL peptide binding
to MHC class II molecules obtained using the immune
epitope database
MHC II Allele1 Start-Stop2 Sequence3 Percentile
Rank4
TgCPB
HLA-DRB1*01:01 10–24 LGTPLPFAALAAILL 0.01
HLA-DRB1*01:01 71–85 ESLFDSIVAEQVVAT 6.21
HLA-DRB1*01:01 228–242 LRFRYLSLKDAKKLM 4.99
HLA-DRB1*01:01 320–334 SQGKRLMPLSAQHTT 2.74
HLA-DRB1*01:01 470–484 SGVYKHVSGLPVGGH 1.58
H2-IAb 8–22 RVLGTPLPFAALAAI 3.83
H2-IAb 59–73 DVLNAFVSPESVESL 3.51
H2-IAb 187–201 VFWESRPASSNAAVA 0.91
H2-IAb 300–314 CGSCWAFASTEAFND 4.46
H2-IAb 549–563 LPGQRAAGARAGAHA 3.19
H2-IAd 15–29 PFAALAAILLLGCMY 1.88
H2-IAd 191–205 SRPASSNAAVALIKK 4.34
H2-IAd 227–241 SLRFRYLSLKDAKKL 1.21
H2-IAd 320–334 SQGKRLMPLSAQHTT 3.19
H2-IAd 428–442 QDTHKATSAYSLRSR 2.52
H2-IEd 182–196 ETGEDVFWESRPASS 17.89
H2-IEd 226–240 VSLRFRYLSLKDAKK 13.43
H2-IEd 351–365 QPGMAWRWFERKGVV 4.77
H2-IEd 399–413 DATLVPRKTPKCRKD 16.82
H2-IEd 432–446 KATSAYSLRSRDDVK 9.89
TgCPL
HLA-DRB1*01:01 60–74 RAWIALVAAAVSLLV 0.04
HLA-DRB1*01:01 46–60 YFWKKFLRQRNFTAR 6.00
HLA-DRB1*01:01 117–131 FSSFQAMYAKSYATE 2.74
HLA-DRB1*01:01 136–150 RRYAIFKNNLVYIHT 3.24
HLA-DRB1*01:01 178–192 LGFKKSRNLKSHHLG 5.20
H2-IAb 27–41 RRGVRAGRPSPPFVV 1.49
H2-IAb 59–73 ARAWIALVAAAVSLL 3.37
H2-IAb 85–99 EDDRAVFPPSPVEDH 3.42
H2-IAb 116–130 AFSSFQAMYAKSYAT 5.68
H2-IAb 226–240 CGSCWAFSTTGALEG 2.49
H2-IAd 22–36 GELHQRRGVRAGRPS 6.17
H2-IAd 57–71 FTARAWIALVAAAVS 0.14
H2-IAd 117–131 FSSFQAMYAKSYATE 2.63
H2-IAd 318–332 DVPRRSEAAMKAALA 0.01
H2-IAd 395–409 RDGYMYMAMHKGEEG 1.82
H2-IEd 42–56 TTRTYFWKKFLRQRN 7.05
H2-IEd 174–188 RRKYLGFKKSRNLKS 13.03
H2-IEd 202–216 PSELPAGVDWRSRGC 28.28
H2-IEd 309–323 KVVKILGFKDVPRRS 21.70
H2-IEd 376–390 KESKKDFWIMKNSWG 24.70
1 H2-IAb, H2-IAd and H2-IEd alleles are mouse MHC class II molecules; the
HLA-DRB1*01:01 allele is a human MHC class II molecule.
2 We chose 15 amino acids for analysis each time.
3 TgCPB or TgCPL sequences.
4 Low percentile = high binding.
Table 4 Ligation strength analysis of TgCPB and TgCPL
for MHC class II molecules using SYFPEITHI
MHC II Allele1 Start-Stop2 Sequence3 Score4
TgCPB
H2-Ad 55–69 FSAEDVLNAFVSPES 31
H2-Ad 76–90 SIVAEQVVATSGNLT 27
H2-Ad 412–426 KDCEEQAYADNVHPF 27
H2-Ad 117–131 AGELLRLLLADSEDM 26
H2-Ak 43–57 LSEDTSVDPRESFSA 24
H2-Ak 72–86 SLFDSIVAEQVVATS 24
H2-Ak 149–163 IVRDSVLVSEKAFPS 24
H2-Ak 37–51 DDSLFPLSEDTSVDP 22
H2-Ed 313–327 NDRLCIRSQGKRLMP 28
H2-Ed 436–450 AYSLRSRDDVKRDMM 28
H2-Ed 229–243 RFRYLSLKDAKKLMG 26
H2-Ed 309–313 TEAFNDRLCIRSQGK 24
H2-Ek 86–100 SGNLTESAPRDRDSA 24
H2-Ek 313–327 NDRLCIRSQGKRLMP 22
H2-Ek 463–477 EDFLSYKSGVYKHVS 22
H2-Ek 37–51 DDSLFPLSEDTSVDP 20
HLA-DRB1*0101 4–18 RKSFRVLGTPLPFAA 35
HLA-DRB1*0101 13–27 PLPFAALAAILLLGC 34
HLA-DRB1*0101 470–484 SGVYKHVSGLPVGGH 33
HLA-DRB1*0101 71–85 ESLFDSIVAEQVVA T 32
TgCPL
H2-Ad 60–74 RAWIALVAAAVSLLV 31
H2-Ad 68–82 AAVSLLVFASFLIQW 30
H2-Ad 192–206 GVATELLNVLPSELP 30
H2-Ad 58–72 TARAWIALVAAAVSL 27
H2-Ak 18–32 GLENGELHQRRGVRA 22
H2-Ak 146–160 VYIHTHNQQGYSYSL 22
H2-Ak 196–210 ELLNVLPSELPAGVD 22
H2-Ak 256–270 ELMDCSRAEGNQSCS 20
H2-Ed 311–325 VKILGFKDVPRRSEA 30
H2-Ed 44–58 RTYFWKKFLRQRNFT 26
H2-Ed 170–184 RDEFRRKYLGFKKSR 26
H2-Ed 369–383 LVGYGTDKESKKDFW 26
H2-Ek 310–324 VVKILGFKDVPRRSE 24
H2-Ek 77–91 SFLIQWQGEDDRAVF 22
H2-Ek 365–379 HGVLLVGYGTDKESK 22
H2-Ek 6–20 THYVSFLNGEDDGLE 20
HLA-DRB1*0101 59–73 ARAWIALVAAAVSLL 34
HLA-DRB1*0101 60–74 RAWIALVAAAVSLLV 31
HLA-DRB1*0101 195–209 TELLNVLPSELPAGV 31
HLA-DRB1*0101 308–322 EKVVKILGFKDVPRR 30
1 H2-Ad, H2-Ak, H2-Ed and H2-Ek alleles are mouse MHC class II molecules; the
HLA-DRB1*0101 allele is a human MHC class II molecule.
2 We chose 15 amino acids for analysis each time.
3 TgCPB or TgCPL sequences.
4 High score = high binding.
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Ethics statement
All experimental procedures using animals in the present
study had received prior approval by the Institutional Ani-
mal Care and Use Committee of Shandong University
under Contract 2011–0015. Humane endpoints to reduce
pain or distress in the experimental animals were employed
via euthanasia. Mice were monitored daily over 8 weeks for
signs of toxoplasmosis, which included difficulties with their
food and water intake, lethargy, or severe ascites. Mice that
showed signs of illness were sacrificed immediately using
CO2 gas; this involved placing the mice in a chamber and
administering CO2 at a concentration of 60% to 70% over a
5-minute exposure time, after which the cervical dislocation
method was sometimes used to ensure that effective eu-
thanasia had occurred.
Results
Prediction of linear-B cell epitopes and Th-cell epitopes
The results of the prediction analyses indicated the pres-
ence of 21 potential epitopes on TgCPB and 17 on TgCPL,
as shown in Tables 1 and 2. The Th-cell epitopes on TgCPB
and TgCPL that were identified by bioinformatic analyses
are predicted to have the ability to bind strongly to MHC
class II molecules (Tables 3 and 4). The binding strength of
the interaction is known to influence the direction of Th
cell differentiation, where, as the binding force increases,
more cells tend to differentiate into Th-1 cells [41,42]. As
such, we speculate that TgCPB and TgCPL are likely to in-
duce Th-1 cell-mediated immune responses.
Prokaryotic and eukaryotic expression vectors for TgCPB
and TgCPL
Recombinant plasmids pET30a-TgCPB and pET30a-
TgCPL were digested with EcoRI and XhoI resulting in
the correct sized fragments and indicating successful
construction of the prokaryotic expression plasmids
(Figure 1A). Similarly, restriction digests of pBudCE4.1-
TgCPB (NotI and XhoI), pBudCE4.1-TgCPL (HindIII and
XbaI), and the dual construct pBudCE4.1-TgCPB-TgCPL
(NotI, XhoI, HindIII and XbaI) confirmed that the re-
combinant eukaryotic expression plasmids had been cor-
rectly made (Figure 1B).
Antibody specificity against rTgCPB and rTgCPL proteases
PVDF membranes from western blots of STAg prepara-
tions were incubated separately with mouse anti-TgCPB
or anti-TgCPL antibodies or pre-immune mouse sera.
The results showed that the mouse anti-TgCPB and
anti-TgCPL antibodies recognized proteins bands of
about 62 kDa and 47 kDa, which is consistent with the
expected sizes of the TgCPB and TgCPL proteins, re-
spectively (Figure 2).
Figure 1 Recombinant cathepsin protease expression plasmids. (A) M: DNA size marker; Lane 1: recombinant pET30a-TgCPB plasmid
digested with EcoRI and XhoI; Lane 2: recombinant pET30a-TgCPL plasmid digested with EcoRI and XhoI. (B) M: DNA size marker; Lane 1:
recombinant pBudCE4.1-TgCPB plasmid digested with NotI and XhoI; lane 2: recombinant pBudCE4.1-TgCPL plasmid digested with HindIII and
XbaI; lane 3: recombinant pBudCE4.1-TgCPB-TgCPL plasmid digested with NotI, XhoI, HindIII and XbaI.
Figure 2 Western blot identification of TgCPB and TgCPL
proteins in tachyzoite-stage parasites.
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Figure 3 Indirect fluorescent antibody detection of recombinant TgCPB and TgCPL proteases on the surface of HEK293 cells. (A1)
pTgCPB-transfected HEK293 cells; (A2) pBudCE4.1-transfected HEK293 cells. (B1) pTgCPL-transfected HEK293 cells; (B2) pBudCE4.1-transfected
HEK293 cells. (C1) pTgCPB/TgCPL-transfected HEK293 cells where pTgCPB/TgCPL expression was detected using the anti-TgCPB antibody as the
primary antibody; (C2) pBudCE4.1-transfected HEK293 cells where the anti-TgCPB antibody was used as the primary antibody. (D1) pTgCPB/
TgCPL-transfected HEK293 cells where the anti-TgCPL antibody was used as the primary antibody; (D2) pBudCE4.1-transfected HEK293 cells
where the anti-TgCPL antibody was used as the primary antibody. High level of laser intensity was used for A1, A2, B1 and B2, lower level of laser
intensity for C1, C2, D1 and D2.
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Identification of protein expression in HEK293 cells using
immunofluorescence assay (IFA) and western blotting
In vitro expression of pTgCPB, pTgCPL and pTgCPB/
TgCPL were evaluated by IFAs at 48h post-transfection. As
shown in Figure 3, green fluorescence was observed in
HEK293 cells, whereas no fluorescence was observed in the
pBudCE4.1 vector transfected cells. Western blotting ana-
lysis confirmed expression of rTgCPB (~62kDa) and rTgCPL
(~47kDa) in HEK293 cells transfected with pTgCPB or
pTgCPL. Both proteins were detected in cells transfected
with the dual expression vector, pTgCPB/TgCPL (Figure 4).
Antibody responses in immunized mice
High levels of immunoglobulin G (IgG) antibodies were
observed in the experimental mice immunized with
pTgCPB, pTgCPL, or pTgCPB/TgCPL. The antibody
levels gradually increased with successive immunizations
and were higher than those of the control groups, which
were immunized with phosphate-buffered saline (PBS)
or pBudCE4.1 (Figure 5). A significant difference was
detected between the experimental groups and the con-
trol groups (P < 0.05). IgG antibody levels in the
pTgCPB/TgCPL group were higher than those of the
Figure 5 Determination of specific IgG antibodies in sera of
immunized mice. Sera from 13 mice per group were collected one day
prior to each immunization and the subtype levels were determined
using enzyme-linked immunosorbent assays. All samples were run in
triplicate. The results are representative of 3 experiments and shown as
the mean of the OD490 ± SD. *, statistically significant differences (P < 0.05)
compared to the phosphate-buffered saline (PBS) or pBudCE4.1 controls.
Figure 6 Distribution of IgG subtypes IgG1 and IgG2a in
immunized mice. Sera from 13 mice per group were collected from
2th week after the final immunization and the subtype levels were
determined using enzyme-linked immunosorbent assays. All samples
were run in triplicate. IgG subtypes IgG1 and IgG2a levels in the sera of
mice two weeks after the last immunization were analyzed using an
enzyme-linked immunosorbent assays. The results are representative of 3
experiments and expressed as the mean of the OD490 ± SD. *, statistically
significant differences (P < 0.05) compared to the control groups.
Table 5 Cytokine production by splenocytea cultures
from immunized BALB/c mice
Group Cytokine production (pg/mL)b
IFN-γ IL-4 IL-10
PBS 47.59 ± 4.63 37.26 ± 2.84 44.34 ± 2.77
PBudCE4.1 48.35 ± 1.86 33.70 ± 3.29 38.70 ± 2.70
pTgCPB 674.93 ± 83.36* 32.58 ± 3.72 34.60 ± 1.92
pTgCPL 585.14 ± 112.03* 32.34 ± 3.87 35.47 ± 1.94
pTgCPB/TgCPL 1182.23 ± 94.28*# 36.11 ± 3.51 34.57 ± 2.14
IFN, interferon; IL, interleukin, PBS, phosphate-buffered saline.
a Splenocytes were obtained from 3 mice per group and were collected at
week 4 after the final immunization.
b Values for IFN-γ at 96 h. Values for IL-10 at 72 h. Values for IL-4 at 24 h.
*Compared with the PBS-adjuvant or pBudCE4.1 controls (P < 0.05); #
compared with pTgCPB or pTgCPB (P < 0.05).
Figure 4 Western blot analysis of TgCPB and TgCPL protein
expression in transfected HEK293 cells. M: protein marker; (1)
HEK293 cells transfected with the recombinant pTgCPB/TgCPL plasmid;
(2) HEK293 cells transfected with the recombinant pTgCPL plasmid;
(3) HEK293 cells transfected with the recombinant pTgCPB plasmid;
(4) HEK293 cells transfected with an empty vector.
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pTgCPB and pTgCPL groups (P < 0.05). However, no
statistical difference was detected between the pTgCPB
and pTgCPL groups (P > 0.05). These results indicate
that the recombinant plasmids encoding TgCPB and
TgCPL induced strong IgG antibody responses in the
mice. Furthermore, the OD value for this group reached
a high level two weeks after the third immunization.
IgG subclass (IgG1 and IgG2a) levels in all of the
groups during the second week after the final immuniza-
tions were investigated to determine whether a Th1- or
Th2-type response was elicited (Figure 6). An apparent
predominance of IgG2a over IgG1 was observed in both
the single-gene or multi-gene vaccine immunized mice,
indicating a shift toward a Th1-type response. Further-
more, mice immunized with pTgCPB/TgCPL generated
higher IgG2a levels than those immunized with pTgCPB
or pTgCPL alone (P < 0.05). However, there was no sig-
nificant difference in the IgG2a levels between the
pTgCPB and pTgCPL groups (P > 0.05).
Cytokine production
The splenocyte supernatant was harvested at different
times and used to measure cytokine production (inter-
feron-γ [IFN-γ], interleukin-4 [IL-4] and IL-10) in the
different groups. As shown in Table 5, mice vaccinated
with pTgCPB/TgCPL generated significantly higher levels
of IFN-γ than mice vaccinated with pTgCPB, pTgCPL,
PBS, or an empty vector (P < 0.05). The level of IFN-γ in
the pTgCPB-immunized mice was higher than that of the
pTgCPL-immunized mice, but the difference was not sta-
tistically significant (P > 0.05). In addition, the low levels of
IL-4 and IL-10 seen in the experimental and control
groups suggested no statistically significant differences
among the groups (P > 0.05). IFN-γ and IL-2 favor Th1-
type immune responses, whereas IL-4 and IL-10 favor
Th2-type responses. These results show that the cellular
immune response induced by the single- or multi-gene
vaccines tended to be a Th1-type response in the mice.
Protective efficacy of DNA vaccination against T. gondii in
mice
To evaluate the level of immunoprotection induced by the
DNA vaccines, all of the mice were challenged intraperito-
neally with the T. gondii RH strain and mortality was
monitored daily until all of the mice showed signs of ill-
ness and were killed (Figure 7). Mice immunized with the
DNA vaccines had dramatically higher survival times than
did the control groups vaccinated with PBS or pBudCE4.1
(P < 0.05). Mice vaccinated with pTgCPB/TgCPL showed a
greater survival time than those vaccinated with pTgCPB
or pTgCPL (P < 0.05). However, no significant difference
was observed between mice immunized with pTgCPB and
those immunized with pTgCPL (P > 0.05).
Discussion
Bioinformatics is an established interdisciplinary science
related to mathematics, statistics, computer science, phys-
ics, biology and medicine [43]. Because of its effectiveness
and low cost, it has been widely used to predict the struc-
ture, function and antigenic epitopes of proteins by esti-
mation of the similarity of the protein of interest to a
sequence of known structure or function [44,45]. As previ-
ously described, we initially used DNAStar software to
analyze the secondary structures of TgCPB and TgCPL,
followed by DNAMAN software to analyze their se-
quences from which we identified many good liner-B cell
epitopes. Secondly, we used two online services (IEDB and
SYFPEITHI) for analyzing Th-cell epitopes and found sev-
eral potential Th-cell epitopes on TgCPB and TgCPL.
Figure 7 Survival curves of the vaccinated BALB/c following Toxoplasma gondii challenge infections. 10 mice per group were challenged
with 1 × 104 tachyzoites of the virulent T. gondii RH strain on the 4th week after the final immunization. Survival was monitored daily for 18 days
post-challenge with the parasites.
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Through the animal experiments, we confirmed that
both TgCPB and TgCPL can induce strong humoral and
cellular immune responses and noted a significantly
higher level of total IgG antibodies, IgG2a, and IFN-γ
than that observed for the controls. These results show
that TgCPB and TgCPL make good vaccine antigens,
thus highlighting the reliability of the bioinformatics ap-
proaches that were used herein.
In the present study, we successfully constructed
pTgCPB and pTgCPL single-gene vaccines and a
pTgCPB/TgCPL multi-gene vaccine. Both single- and
multi-gene vaccines produced humoral and cellular im-
mune responses in the murine host. The multi-gene vac-
cine was superior to the single-gene vaccine; it elicited
stronger immune responses and more effective protec-
tion against T. gondii infection. Importantly, all of the
mice in the experimental groups immunized with
pTgCPB, pTgCPL, or pTgCPB/TgCPL displayed strong
humoral immune responses as shown by their high IgG
levels. The high levels of IgG2a and IFN-γ and low levels
of IL-4 and IL-10 suggest that the cellular immune re-
sponses were mediated by Th-1 cells [46,47]. These ex-
periments were conducted in BALB/c mice; however, it
would be interesting to test other strains of mice with
different MCH backgrounds to investigate the range of
immune responses to the vaccines.
The survival times of all of the mice in the five groups
after intraperitoneal challenge with 1 × 104 tachyzoites of
the virulent RH strain of T. gondii were recorded. Com-
pared to the mice in the control groups, the immunized
mice showed protection against T. gondii infection: all
mice in the control groups showed signs of illness and
were killed within 8 days post-challenge, whereas mice im-
munized with pTgCPB, pTgCPL, or pTgCPB/TgCPL had
significantly increased survival rates. Mice immunized
with pTgCPB/TgCPL showed stronger humoral and cellu-
lar immune responses and significantly prolonged survival
times than mice in the pTgCPB and pTgCPL groups. All
of the mice showed signs of illness and were killed by day
16 post-challenge. The results indicate, therefore, that the
DNA vaccines did not provide complete protection against
T. gondii RH tachyzoite infection.
Finally, the pBudCE4.1 vector should be mentioned.
This vector was chosen to for expression of the multi-
gene vaccine because it has two promoters (CMV and
EF-1α), thus ensuring that TgCPB and TgCPL can both
be expressed whilst avoiding mutual interference.
Conclusions
In this study, we used bioinformatics approaches to
identify antigenic epitopes on TgCPB and TgCPL prote-
ases. Thereafter, we made single-gene (pTgCPB and
pTgCPL) and multi-gene (pTgCPB/TgCPL) DNA vac-
cines to evaluate the level of immunoprotection induced
in mice immunized with such vaccines. The experimen-
tal results are consistent with the bioinformatics predic-
tions that the antigenic epitopes on these proteins
should induce appropriate immune responses. Hence,
these results show that bioinformatics analyses to predict
antigenic epitopes on proteins can be a useful tool for
vaccine research. When the vaccinated mice were given
a challenge infection with T. gondii RH tachyzoites, we
found that the DNA vaccine constructs did not provide
complete protection against infection, however. Never-
theless, DNA vaccines merit further investigated as a
strategy for controlling T. gondii infection.
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